The Pharmacokinetics and Mass Spectrometry (PKMS) Core aims to facilitate researchers' efforts to discover new medicines, obtain research funding, file patent applications, and publish academic research findings for both preclinical and clinical pharmacokinetic applications, including lead compound modeling, dose optimization, and clinical trials. 


About the Core


The PKMS Core at the University of Michigan was established in 2009 to provide services for both preclinical and clinical researchers.

In the core's short history, we have studied the preclinical PK and drug metabolism of more than 4000 compounds and have been involved in 20 human clinical PK studies. We have contributed to more than 150 grant applications, which resulted in over $43 million in funding to the University of Michigan. We have provided services to more than 70 U-M labs, and 20 external labs. Our work has resulted in over 50 joint manuscripts, with five patents issued and six pending. 

We can work with you either by joining your grant proposals as collaborators, for which we provide consultation as well as PK services, or fee-for-service via recharge. Please contact the PK Core assistant director, Dr. Bo Wen, if you are interested in working with us. 

The PK Core is supported by the College of Pharmacy, the Comprehensive Cancer Center, and the Center for Discovery of New Medicines.




Download our informational flyer:



LCMS bioanalysis:

A. Advanced LC-MS/MS bioanalysis method development.

B. Method transfer and method qualification.

C. Quantitative analysis of small molecular and proteins from biological samples, or food and environment samples.

D. Drug and metabolite analysis to support PK/PD study on medicinal research.

E. Bioanalysis for clinical study by validated method according to FDA Guidance.

F. Chemical compound identification and structure elucidation.

In vitro and In vivo ADME

A. Microsomal stability, Plasma stability, S9 stability, Hepatocyte stability,

B. Cytochrome P450 inhibition, Cytochrome P450 induction, Cytochrome P450 reaction phenotyping.

C. Plasma protein binding, Brain tissue binding, Blood to plasma ratio.

D. Metabolite identification and soft spot identification of target compounds.

E. Tissue bioanalysis including plasma and other organs from in vivo biodistribution study.

F. Oral bioavailability of drugs in rodent modes, or dogs.

G. Max tolerated dose with dose escalation protocol.

H. In vivo screening study with rodent to gain rapid insight into the compounds ADME behavior.

I. In vivo PK study with rodent or dogs to gain broader insight into the compounds PK profile.  

J. Support customer designed animal PK study, including tumor mice model.

Clinical Pharmacokinetic studies

A. Clinical study development.

B. Data analysis with non-compartment model or non-linear mixed effects modeling.

C. Modeling and simulation with Population-PK analysis.

D. Precision medicine.

Advanced mass spectrometry application

A. Mass spectrometry imaging on tissue samples to visualize or provide spatial information of drugs and their metabolites, peptides, lipids, metabolisms, and proteins and their modification.

B. Biomarker identification and characterization.

C. Targeted metabolomics for bile acid, amino acid and glucose.

D. Targeted lipidomics. 

Listing Row

Monday, December 12, 2016
Monday, December 12, 2016